You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Aflibercept for treating diabetic macular oedema

  • Technology appraisal guidance
  • Reference number: TA346
  • Published:  22 July 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The company's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Review of guidance
  • 7 Appraisal Committee members, guideline representatives and NICE project team
  • 8 Sources of evidence considered by the Committee
  • About this guidance

6 Review of guidance

6.1 The guidance on this technology will be considered for review 3 years after publication of the guidance. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
July 2015


Next page 7 Appraisal Committee members, guideline representatives and NICE project team Previous page 5 Implementation